SequelSEC

TANDEM DIABETES CARE INC TNDM

Surgical & Medical Instruments & Apparatus · CIK 0001438133 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$254.56M
Fiscal year ended 2026-06-30
Operating income
-$13.79M
Fiscal year ended 2026-06-30
Free cash flow
-$38.68M
Fiscal year ended 2026-06-30

TANDEM DIABETES CARE INC (TNDM) reported revenue of $254.56M and net income of -$21.17M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from TANDEM DIABETES CARE INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

TANDEM DIABETES CARE INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$254.56M$247.22M$290.38M$249.25M$240.68M$234.42M$282.65M$243.97M$221.91M$191.67M
Cost of revenue$109.78M$110.43M$122.92M$114.96M$114.82M$116.02M$125.19M$119.32M$109.12M$97.00M
Gross profit$144.78M$136.79M$167.46M$134.29M$125.86M$118.41M$157.46M$124.65M$112.79M$94.67M
Operating income-$13.79M-$17.43M$8.29M-$22.86M-$51.81M-$120.88M-$581.00K-$26.09M-$30.77M-$41.68M
Net income-$21.17M-$20.39M-$589.00K-$21.16M-$52.40M-$130.56M$755.00K-$23.25M-$30.81M-$42.72M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 69.01Mshares 68.40Mshares 68.01Mshares 67.65Mshares 67.05Mshares 66.40Mshares 66.16Mshares 65.54Mshares 64.99Mshares 65.33M
Pretax income-$20.66M-$19.88M$4.68M-$25.14M-$57.72M-$122.09M$16.00K-$22.61M-$29.74M-$39.53M
Income tax expense$510.00K$516.00K$5.27M-$3.98M-$5.32M$8.47M-$739.00K$637.00K$1.07M$3.19M
Diluted EPS$-0.31$-0.30$-0.01$-0.31$-0.78$-1.97$0.01$-0.35$-0.47$-0.65
Selling, general & administrative$111.64M$108.19M$113.10M$108.44M$109.60M$113.85M$105.84M$99.64M$94.24M$90.11M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

TANDEM DIABETES CARE INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$62.82M$179.32M$90.63M$91.95M$64.11M$53.57M$69.23M$49.04M$47.70M$58.98M
Total assets$1.15B$1.15B$881.11M$874.65M$875.74M$922.14M$967.66M$957.73M$937.50M$941.04M
Current assets$804.64M$887.10M$618.14M$616.94M$614.82M$663.44M$724.49M$752.83M$733.39M$735.19M
Total liabilities$1.02B$1.02B$725.94M$741.69M$742.45M$766.85M$704.56M$720.02M$703.63M$697.98M
Current liabilities$253.00M$247.96M$242.72M$252.54M$251.69M$288.18M$247.05M$259.28M$240.61M$192.97M
Total equity incl. NCI$130.39M$132.40M$155.17M$132.96M$133.28M$155.29M$263.10M$237.71M$233.88M$243.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$135.11M$126.40M$128.77M$137.28M$142.57M$141.16M$149.61M$152.44M$161.66M$153.89M
Accounts receivable$162.06M$140.67M$165.49M$125.94M$128.44M$126.56M$114.58M$107.19M$98.12M$92.96M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$602.58M$601.77M$310.04M$309.59M$309.15M$308.70M$308.27M$307.83M$307.39MUnavailable
Accounts payable$64.13M$59.86M$47.07M$47.48M$55.84M$59.80M$44.73M$48.75M$47.78M$48.14M

Cash flow

TANDEM DIABETES CARE INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$34.63M$11.05M$9.79M$8.26M-$9.50M-$18.28M$10.72M$26.78M-$5.28M-$8.00M
Capital expenditures$4.05M$6.27M$6.68M$4.09M$6.21M$2.96M$3.07M$5.24M$6.47M$4.46M
Investing cash flow-$87.34M-$195.45M-$14.98M$20.54M$58.13M$9.19M$5.01M-$19.90M-$3.54M-$5.06M
Financing cash flow$2.15M$274.16M$2.60M-$1.57M-$39.71M-$4.69M$2.30M-$4.52M-$3.00M$13.59M
Net change in cash-$116.51M$88.69M-$1.31M$27.84M$10.54M-$15.66M$20.20M$1.34M-$11.28M$111.00K
Stock-based compensation$15.74M$15.66M$20.11M$21.14M$25.64M$25.49M$28.17M$26.28M$24.90M$22.04M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0$0$0$0$0$0$0$30.00M
Depreciation & amortization$4.47M$4.50M$4.50M$4.49M$4.37M$4.31M$4.24M$4.21M$4.11M$4.04M

Derived

TANDEM DIABETES CARE INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$38.68M$4.79M$3.10M$4.17M-$15.70M-$21.24M$7.65M$21.54M-$11.74M-$12.45M
Gross margin56.9%55.3%57.7%53.9%52.3%50.5%55.7%51.1%50.8%49.4%
Operating margin-5.4%-7.1%2.9%-9.2%-21.5%-51.6%-0.2%-10.7%-13.9%-21.7%
FCF margin-15.2%1.9%1.1%1.7%-6.5%-9.1%2.7%8.8%-5.3%-6.5%
SBC / revenue6.2%6.3%6.9%8.5%10.7%10.9%10.0%10.8%11.2%11.5%
Current ratio3.18x3.58x2.55x2.44x2.44x2.30x2.93x2.90x3.05x3.81x
Revenue YoY growth5.8%5.5%2.7%2.2%8.5%22.3%43.6%31.4%13.3%13.2%
Net margin-8.3%-8.2%-0.2%-8.5%-21.8%-55.7%0.3%-9.5%-13.9%-22.3%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue1.6%2.5%2.3%1.6%2.6%1.3%1.1%2.1%2.9%2.3%
Long-term debt / equity4.62xUnavailable2.00x2.33xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable112.6%UnavailableUnavailableUnavailable-4618.8%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TNDM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.